Journal
LEUKEMIA
Volume 32, Issue 2, Pages 450-461Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/leu.2017.230
Keywords
-
Categories
Funding
- Faculty of Medicine, Masaryk University [MUNI/A/1106/2016, ROZV/24/LF/2016]
- project of MH CR [16-29447A]
- project of MEYS CR [LM2015064 EATRIS]
- project of CEITEC [LQ1601]
- project of TACR [TE02000058]
- Czech Leukemia Study Group for Life (CELL)
- Genomics Core Facility CEITEC under MEYS CR project [LM2011020]
Ask authors/readers for more resources
The multistep process of TP53 mutation expansion during myeloproliferative neoplasm (MPN) transformation into acute myeloid leukemia (AML) has been documented retrospectively. It is currently unknown how common TP53 mutations with low variant allele frequency (VAF) are, whether they are linked to hydroxyurea (HU) cytoreduction, and what disease progression risk they carry. Using ultra-deep next-generation sequencing, we examined 254 MPN patients treated with HU, interferon alpha-2a or anagrelide and 85 untreated patients. We found TP53 mutations in 50 cases (0.2-16.3% VAF), regardless of disease subtype, driver gene status and cytoreduction. Both therapy and TP53 mutations were strongly associated with older age. Over-time analysis showed that the mutations may be undetectable at diagnosis and slowly increase during disease course. Although three patients with TP53 mutations progressed to TP53-mutated or TP53-wild-type AML, we did not observe a significant age-independent impact on overall survival during the follow-up. Further, we showed that complete p53 inactivation alone led to neither blast transformation nor HU resistance. Altogether, we revealed patient's age as the strongest factor affecting low-burden TP53 mutation incidence in MPN and found no significant age-independent association between TP53 mutations and hydroxyurea. Mutations may persist at low levels for years without an immediate risk of progression.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available